Business Context and Reporting Period
Company: Can-Fite Biopharma Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: September 10, 2019
Reporting Period: Month of September 2019
The filing serves to incorporate by reference a press release regarding a new strategic collaboration. The registrant files annual reports on Form 20-F.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report of a corporate event and does not contain financial statements or performance metrics.
Material Changes
New Collaboration Agreement: On September 10, 2019, the Company entered into a collaboration agreement with Univo Pharmaceuticals (TASE:UNVO), a medical cannabis company.
- Objective: To identify and co-develop specific formulations of cannabis components.
- Target Indications: Treatment of cancer, inflammatory, autoimmune, and metabolic diseases.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates specific paragraphs from the attached press release (Exhibit 99.1) into the Company's Registration Statements on Form S-8 and Form F-3. These paragraphs include "Forward Looking Statements."
Risks and Contingencies: The filing text does not explicitly detail specific risks or contingencies beyond the standard incorporation of forward-looking statements found in the referenced press release.
Investor Verification Checklist
- Review the full text of the attached Press Release (Exhibit 99.1) for specific terms of the collaboration with Univo Pharmaceuticals.
- Verify the financial impact and funding status of the new collaboration in subsequent quarterly or annual reports.
- Monitor the progress of the co-development of cannabis formulations for the specified disease indications.
- Check for any updates to the Registration Statements (Form S-8 and Form F-3) regarding the incorporated forward-looking statements.